Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Mepolizumab Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_16552026_0926

    Mepolizumab (Nucala) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_16552026_0926 alerts

    Get alerted when Policy ID_CHS_16552026_0926 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for mepolizumab (Nucala) for specified FDA-approved indications and compendial uses, including chronic rhinosinusitis with nasal polyps, severe eosinophilic asthma, eosinophilic COPD, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMepolizumab (Nucala) Coverage Criteria
    Policy CodePolicy ID_CHS_16552026_0926
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit the documentation specified for the applicable indication and request type to initiate or continue prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Covered indication categories
    RequiredPrior authorization documentation
    6 or 12 monthsAuthorization periods
    Not coveredAcute bronchospasm or status asthmaticus

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    100 mg every 4 weeks
    Standard adult dose for asthma, COPD, or CRSwNP

    Covered Indications, Limitations, and Exclusions

    Covered indications

    Covered when the member has a listed FDA-approved indication or covered compendial use, all approval criteria are met, and no exclusions apply.

    Covered indication: The member has one of the following covered indications: chronic rhinosinusitis with nasal polyps in adults 18 years and older with inadequate response to nasal corticosteroids; severe asthma with an eosinophilic phenotype in members 6 years and older; inadequately controlled COPD with an eosinophilic phenotype in adults; HES in members 12 years and older present for at least 6 months without an identifiable non-hematologic secondary cause; or EGPA in adults.

    Limitation of use

    Use is not covered for the following limitation.

    Limitation of use: Nucala is not indicated for the relief of acute bronchospasm or status asthmaticus.

    Experimental or investigational indications

    Other indications are not medically necessary.

    Uncovered indication: The requested use is not one of the listed FDA-approved or covered compendial indications.

    Such indications are considered experimental or investigational and are not medically necessary.

    Acute bronchospasm or status asthmaticus is not covered because mepolizumab (Nucala) is not indicated for relief of these conditions.

    Use for indications other than the listed FDA-approved or covered compendial indications is not covered.

    Coverage is excluded for FIP1L1-PDGFRA kinase-positive hypereosinophilic syndrome (HES).

    Coverage is excluded for HES secondary to a non-hematologic cause, including drug hypersensitivity, parasitic helminth infection, human immunodeficiency virus (HIV) infection, or non-hematologic malignancy.

    Mepolizumab cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Indications other than the listed FDA-approved or covered compendial uses are considered experimental or investigational and are not medically necessary.

    Initial Authorization Criteria

    Asthma initial therapy

    Asthma initial requests require treatment-history and disease-marker documentation.

    Asthma initial request: Provide documentation of previously tried medications, including drug, dose, frequency, and duration; and provide pretreatment blood eosinophil count or documentation of dependence on systemic corticosteroids, when applicable.

    EGPA initial therapy

    EGPA initial requests require eosinophil and prior-treatment documentation.

    EGPA initial request: Provide pretreatment blood eosinophil count or percentage where applicable; documentation of previously tried medications with drug, dose, frequency, and duration; and the clinical reason to avoid therapy when therapy is not advisable.

    HES initial therapy

    HES initial requests require eosinophil, molecular testing, and prior-treatment documentation.

    Continuation Authorization Criteria

    Asthma continuation — improvement in asthma control

    Continuation requests for asthma require evidence of improvement in asthma control.

    Asthma continuation response

    • Improved control

      • Reduction in the frequency and/or severity of symptoms and exacerbations.
      • Reduction or discontinuation of the daily maintenance oral corticosteroid dose.
    • Submit chart notes or medical record documentation supporting the improvement.

    EGPA continuation — beneficial treatment response

    Continuation requests for EGPA require evidence of beneficial response.

    Indication-Specific Pathways

    Initial or severe asthma therapy — all authorization criteria

    Authorization of 6 months may be granted for severe asthma when all criteria are met.

    Severe asthma authorization

    • Eligibility pathway

      • Member is 6 years of age or older and has a baseline blood eosinophil count of at least 150 cells per microliter.
      • Member is dependent on oral systemic corticosteroids.
    • Uncontrolled asthma

      • At least two exacerbations requiring oral or injectable corticosteroids within the past 12 months.

    Prior Biologic Therapy Requirements

    StepRequirementTimeframe
    1Previously received a biologic drug indicated for asthma, such as Dupixent or CinqairWithin the past 12 months
    StepRequirementTimeframe
    1Previously received a biologic drug indicated for eosinophilic granulomatosis with polyangiitis (EGPA), such as FasenraWithin the past 12 months
    StepRequirementTimeframe
    1Previously received a biologic drug indicated for chronic rhinosinusitis with nasal polyps (CRSwNP), such as Dupixent, Tezspire, or XolairWithin the past 12 months
    StepRequirementTimeframe
    1Previously received a biologic drug indicated for chronic obstructive pulmonary disease (COPD), such as DupixentWithin the past 12 months
    StepRequirementTimeframe
    1Previously received a biologic drug indicated for COPD, such as DupixentWithin the past 12 months

    Clinical Thresholds and Objective Measures

    Asthma Threshold
    Asthma baseline blood eosinophil countAt least 150 cells per microliter
    Applicable conditionSevere asthma with an eosinophilic phenotype
    Therapy contextUsed as an alternative eligibility pathway for severe asthma authorization
    EGPA Threshold
    EGPA eosinophil countMore than 1000 cells per microliter or a blood eosinophil level greater than 10%
    Minimum age18 years or older
    Concurrent treatment

    Authorization, Documentation, and Decision Rules

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required to initiate review for Nucala. Submit the documentation applicable to the indication and request type.

    Documentation Required

    Required Prescriber Specialty

    Nucala must be prescribed by or in consultation with the applicable specialty provider.

    • EGPA: allergist/immunologist, pulmonologist, or rheumatologist
    • Asthma: allergist/immunologist or pulmonologist
    • HES: allergist/immunologist, hematologist, or cardiologist
    • COPD: pulmonologist or allergist/immunologist
    • CRSwNP: allergist/immunologist or otolaryngologist

    Policy Background

    Mepolizumab (Nucala) is covered as add-on maintenance therapy for selected eosinophilic airway diseases and as treatment for hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis. Covered uses include chronic rhinosinusitis with nasal polyps, severe eosinophilic asthma, eosinophilic chronic obstructive pulmonary disease, HES meeting the applicable age and duration requirements, and EGPA. It is not used for acute bronchospasm or status asthmaticus.

    Terms and Clinical Definitions

    Definitions
    AbbreviationCRSwNP
    Full termChronic rhinosinusitis with nasal polyps
    Covered populationAdults 18 years and older with inadequate response to nasal corticosteroids
    Definitions
    AbbreviationHES
    Full termHypereosinophilic syndrome
    Covered populationAdults and pediatric patients 12 years and older with HES present for at least 6 months without an identifiable non-hematologic secondary cause

    Mepolizumab Dosing Limits

    Nucala Asthma Quantity Limit
    RouteSubcutaneous
    Members 12 years or older100 mg every 4 weeks
    Members 6 to less than 12 years40 mg every 4 weeks
    Nucala COPD Quantity Limit
    RouteSubcutaneous
    Minimum age18 years or older
    Maximum regimen100 mg every 4 weeks

    Administration Route

    Billing Rule

    Administer the regimen subcutaneously

    The specified maximum dosing regimens are administered subcutaneously.

    • Asthma: 100 mg every 4 weeks for members 12 years or older; 40 mg every 4 weeks for members 6 to less than 12 years
    • COPD and CRSwNP: 100 mg every 4 weeks for members 18 years or older
    • EGPA and HES: 300 mg every 4 weeks as 3 separate 100-mg injections
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMepolizumab (Nucala) Coverage Criteria
    Policy CodePolicy ID_CHS_16552026_0926
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit the documentation specified for the applicable indication and request type to initiate or continue prior authorization review.
    SourceLink
    On This Page
    Covered Indications, Limitations, and ExclusionsInitial Authorization CriteriaContinuation Authorization CriteriaIndication-Specific PathwaysPrior Biologic Therapy RequirementsClinical Thresholds and Objective MeasuresAuthorization, Documentation, and Decision RulesPolicy BackgroundTerms and Clinical DefinitionsMepolizumab Dosing LimitsAdministration Route
    HES initial request: Provide pretreatment blood eosinophil count; FIP1L1-PDGFRA fusion gene test results; and documentation of previously tried medications with drug, dose, frequency, and duration.

    CRSwNP initial therapy

    CRSwNP initial requests require prior-treatment and objective nasal disease documentation.

    CRSwNP initial request: Provide documentation of previously tried medications with drug, dose, frequency, and duration, or the clinical reason therapy is not advisable; and provide nasal endoscopy, anterior rhinoscopy, or CT findings, Meltzer Clinical Score, or endoscopic nasal polyp score when applicable.

    Asthma — 6-month authorization criteria

    Authorization of 6 months may be granted for severe asthma when all applicable criteria are met.

    Severe asthma criteria

    • Age or disease-marker pathway

      • Member is 6 years of age or older and has a baseline blood eosinophil count of at least 150 cells per microliter.
      • Member is dependent on oral systemic corticosteroids.
    • Uncontrolled asthma

      • At least two asthma exacerbations requiring oral or injectable corticosteroid treatment within the past 12 months.
      • At least one asthma exacerbation resulting in hospitalization or emergency medical care within the past 12 months.
      • Poor symptom control, including frequent symptoms or reliever use, activity limitation, or night waking due to asthma.
    • Inadequate asthma control despite adherence to optimized high-dose inhaled corticosteroid therapy and an additional controller.

      Additional controller may be a LABA, LAMA, leukotriene modifier, or sustained-release theophylline.

    • Member will continue maintenance asthma treatments, such as an inhaled corticosteroid and additional controller, with mepolizumab.

    HES — 12-month authorization criteria

    Authorization of 12 months may be granted for HES when all criteria are met.

    HES criteria

    • Blood eosinophil count is at least 1000 cells per microliter.≥ 1000 cells/µL
    • Member is 12 years of age or older.≥ 12 years
    • Mepolizumab will not be used as monotherapy.
    • Member has had HES for at least 6 months.≥ 6 months
    • Member has been on a stable dose of HES therapy, such as an oral corticosteroid, immunosuppressive therapy, and/or cytotoxic therapy.
    • Member has experienced at least two HES flares within the past 12 months.≥ 2 flares in 12 months

    CRSwNP — 6-month authorization criteria

    Authorization of 6 months may be granted for CRSwNP when all criteria are met.

    CRSwNP criteria

    • Member is 18 years of age or older and has bilateral nasal polyposis with chronic sinusitis symptoms despite intranasal corticosteroid treatment for at least 4 weeks, unless contraindicated or not tolerated.≥ 18 years; ≥ 4 weeks treatment
    • Prior treatment

      • Member has had prior sino-nasal surgery.
      • Systemic corticosteroid treatment within the last 24 months was ineffective, unless contraindicated or not tolerated.
    • Objective polyp severity

      • Bilateral nasal endoscopy, anterior rhinoscopy, or CT shows polyps reaching below the lower border of the middle turbinate or beyond in each nostril.
      • Meltzer Clinical Score is 2 or higher in both nostrils.≥ 2 in both nostrils
      • Total endoscopic nasal polyp score is at least 5, with a minimum score of 2 for each nostril.≥ 5 total; ≥ 2 per nostril
    • Member has nasal blockage, congestion, or obstruction plus rhinorrhea, reduced or lost smell, or facial pain or pressure.
    • Member will continue daily intranasal corticosteroid treatment unless contraindicated or not tolerated.

    COPD — 12-month authorization criteria

    Authorization of 12 months may be granted for COPD when all criteria are met.

    COPD criteria

    • Diagnosis is confirmed by post-bronchodilator spirometry showing FEV1/FVC less than 0.7.FEV1/FVC < 0.7 post-bronchodilation
    • Member is 18 years of age or older and demonstrates classic COPD signs or symptoms.≥ 18 years
    • Inadequate disease control

      • At least two moderate exacerbations in the past 12 months treated with systemic glucocorticoids, antibiotics, or both.≥ 2 moderate exacerbations
      • At least one severe exacerbation requiring hospitalization or emergency medical care.≥ 1 severe exacerbation
    • Absolute blood eosinophil count is at least 300 cells per microliter before initiating therapy.≥ 300 cells/µL
    • Maintenance inhaler regimen

      • Member is receiving maintenance inhaled triple therapy with an ICS, LAMA, and LABA.
      • Member is receiving a LAMA and LABA and has a contraindication to ICS.
    • Member will continue maintenance COPD treatment with mepolizumab.

    Initial Therapy - COPD

    Initial COPD authorization may be granted for 12 months when all listed criteria are met.

    Initial COPD therapy

    • Confirmed COPD by post-bronchodilator FEV1/FVC less than 0.7; member is 18 years of age or older; member has classic COPD signs or symptoms; and pretreatment absolute blood eosinophil count is at least 300 cells per microliter.FEV1/FVC < 0.7; eosinophils ≥ 300 cells/µL
    • Exacerbation history

      • At least two moderate exacerbations in the past 12 months treated with systemic glucocorticoids, antibiotics, or both.
      • At least one severe exacerbation requiring hospitalization or emergency medical care.
    • Maintenance inhaler regimen

      • Currently receiving inhaled triple therapy consisting of ICS, LAMA, and LABA.
      • Currently receiving LAMA and LABA with a contraindication to ICS.
    • Member will continue maintenance COPD treatment in combination with mepolizumab.
    EGPA continuation response: Submit chart notes or medical record documentation supporting beneficial response to treatment.

    HES continuation — improvement and fusion gene test results

    Continuation requests for HES require evidence of improvement and fusion gene test results.

    HES continuation documentation

    • Documentation supports improvement in HES control.
    • FIP1L1-PDGFRA fusion gene test results are provided.

    CRSwNP continuation — positive clinical response

    Continuation requests for CRSwNP require evidence of positive clinical response.

    CRSwNP continuation response: Submit chart notes or medical record documentation supporting positive clinical response.

    Asthma continuation — all listed criteria

    Continuation of asthma therapy may be authorized for 12 months when all criteria are met.

    Asthma continuation

    • Improved asthma control

      • Reduction in the frequency and/or severity of symptoms and exacerbations.
      • Reduction or discontinuation of the daily maintenance oral corticosteroid dose.
    • Member is 6 years of age or older.≥ 6 years
    • Member will continue maintenance asthma treatments, such as ICS and an additional controller, with mepolizumab.

    Eosinophilic Granulomatosis with Polyangiitis continuation — all listed criteria

    Continuation of EGPA therapy may be authorized for 12 months when all criteria are met.

    EGPA continuation

    • Beneficial response

      • Reduction in the frequency of relapses.
      • Reduction or discontinuation of the daily oral corticosteroid dose.
      • No active vasculitis.
    • Member is 18 years of age or older.≥ 18 years

    Hypereosinophilic Syndrome continuation — both listed criteria

    Continuation of HES therapy may be authorized for 12 months when both criteria are met.

    HES continuation

    • Member has experienced a reduction in HES flares since starting mepolizumab.
    • Member is 12 years of age or older.≥ 12 years

    Chronic Rhinosinusitis with Nasal Polyps continuation — all listed criteria

    Continuation of CRSwNP therapy may be authorized for 12 months when all criteria are met.

    CRSwNP continuation

    • Member has achieved or maintained a positive clinical response, evidenced by improvement in signs and symptoms or reduction in corticosteroid use.
    • Member is 18 years of age or older.≥ 18 years
    • Member will continue daily intranasal corticosteroid treatment unless contraindicated or not tolerated.

    Chronic Obstructive Pulmonary Disease continuation — all listed criteria

    Continuation of COPD therapy may be authorized for 12 months when all criteria are met.

    COPD continuation

    • Member has achieved or maintained a positive clinical response or disease stabilization, such as decreased exacerbations or improved pre-bronchodilator FEV1.
    • Member is 18 years of age or older.≥ 18 years
    • Member will continue maintenance COPD treatments, such as ICS with LAMA and LABA or LAMA and LABA, with mepolizumab.
    At least one exacerbation resulting in hospitalization or emergency medical care.
  1. Poor symptom control with frequent symptoms or reliever use, activity limitation, or night waking.
  2. Inadequate control despite adherence to optimized high-dose ICS and an additional controller.
  3. Member will continue maintenance asthma treatment with mepolizumab.
  4. Asthma after prior biologic therapy — 6-month authorization

    Authorization of 6 months may be granted for members who previously received an asthma biologic within the past 12 months.

    Asthma after prior biologic therapy

    • Member is 6 years of age or older.≥ 6 years
    • Member previously received a biologic indicated for asthma within the past 12 months.Within 12 months

      Examples include Dupixent and Cinqair.

    • Member will continue maintenance asthma treatments, such as ICS and an additional controller, with mepolizumab.

    Hypereosinophilic syndrome — all criteria and 12-month authorization

    Authorization of 12 months may be granted for HES when all criteria are met.

    HES authorization

    • Blood eosinophil count is at least 1000 cells per microliter.≥ 1000 cells/µL
    • Member is 12 years of age or older and has had HES for at least 6 months.
    • Member is on a stable dose of HES therapy and will not use mepolizumab as monotherapy.
    • Member has experienced at least two HES flares within the past 12 months.≥ 2 flares

    Chronic rhinosinusitis with nasal polyps — all criteria and 6-month authorization

    Authorization of 6 months may be granted for CRSwNP when all criteria are met.

    CRSwNP authorization

    • Member is 18 years of age or older and has bilateral nasal polyposis with chronic sinusitis symptoms despite at least 4 weeks of intranasal corticosteroid treatment.
    • Prior treatment

      • Prior sino-nasal surgery.
      • Ineffective systemic corticosteroid treatment within the last 24 months, unless contraindicated or not tolerated.
    • Objective polyp severity

      • Polyps reach below the lower border of the middle turbinate or beyond in each nostril.
      • Meltzer Clinical Score is at least 2 in both nostrils.
      • Total endoscopic nasal polyp score is at least 5, with at least 2 for each nostril.
    • Nasal blockage, congestion, or obstruction plus rhinorrhea, reduced or lost smell, or facial pain or pressure.
    • Member will continue daily intranasal corticosteroid treatment unless contraindicated or not tolerated.

    Chronic obstructive pulmonary disease — all criteria and 12-month authorization

    Authorization of 12 months may be granted for COPD when all criteria are met.

    COPD authorization

    • Post-bronchodilator spirometry confirms FEV1/FVC less than 0.7.FEV1/FVC < 0.7
    • Member is 18 years of age or older and has classic COPD signs or symptoms.
    • Exacerbation history

      • At least two moderate exacerbations treated with systemic glucocorticoids, antibiotics, or both in the past 12 months.
      • At least one severe exacerbation requiring hospitalization or emergency medical care.
    • Pretreatment absolute blood eosinophil count is at least 300 cells per microliter.
    • Maintenance therapy

      • Current inhaled triple therapy with ICS, LAMA, and LABA.
      • Current LAMA and LABA therapy with a contraindication to ICS.
    • Member will continue maintenance COPD treatment with mepolizumab.

    Prior biologic therapy pathways

    For members previously treated with an indication-specific biologic within the past 12 months, the applicable indication-specific authorization pathway may be used.

    Prior biologic pathway

    • Asthma: previously received a biologic indicated for asthma, such as Dupixent or Cinqair, within the past 12 months.
    • EGPA: previously received a biologic indicated for EGPA, such as Fasenra, within the past 12 months.
    • CRSwNP: previously received a biologic indicated for CRSwNP, such as Dupixent, Tezspire, or Xolair, within the past 12 months.
    • COPD: previously received a biologic indicated for COPD, such as Dupixent, within the past 12 months.

    Initial Therapy - COPD

    Initial COPD authorization may be granted for 12 months when all criteria are met.

    Initial COPD authorization

    • COPD is confirmed by post-bronchodilator FEV1/FVC less than 0.7; member is at least 18 years old; and member has classic COPD signs or symptoms.
    • Inadequate control

      • At least two moderate exacerbations in the past 12 months treated with systemic glucocorticoids, antibiotics, or both.
      • At least one severe exacerbation requiring hospitalization or emergency medical care.
    • Pretreatment absolute blood eosinophil count is at least 300 cells per microliter.
    • Maintenance inhalers

      • Current ICS, LAMA, and LABA triple therapy.
      • Current LAMA and LABA therapy with a contraindication to ICS.
    • Member will continue maintenance COPD treatment with mepolizumab.

    Continuation Therapy - Asthma

    Continuation of asthma therapy may be authorized for 12 months when all criteria are met.

    Asthma continuation

    • Improved asthma control

      • Reduction in the frequency and/or severity of symptoms and exacerbations.
      • Reduction or discontinuation of daily maintenance oral corticosteroid dose.
    • Member is at least 6 years old.
    • Member will continue maintenance asthma treatment with mepolizumab.

    Continuation Therapy - EGPA

    Continuation of EGPA therapy may be authorized for 12 months when all criteria are met.

    EGPA continuation

    • Beneficial response

      • Reduction in relapse frequency.
      • Reduction or discontinuation of daily oral corticosteroid dose.
      • No active vasculitis.
    • Member is at least 18 years old.

    Continuation Therapy - HES

    Continuation of HES therapy may be authorized for 12 months when both criteria are met.

    HES continuation

    • Reduction in HES flares since starting mepolizumab.
    • Member is at least 12 years old.

    Continuation Therapy - CRSwNP

    Continuation of CRSwNP therapy may be authorized for 12 months when all criteria are met.

    CRSwNP continuation

    • Positive clinical response, evidenced by improvement in CRSwNP signs and symptoms or reduction in corticosteroid use.
    • Member is at least 18 years old.
    • Member will continue daily intranasal corticosteroid treatment unless contraindicated or not tolerated.

    Continuation Therapy - COPD

    Continuation of COPD therapy may be authorized for 12 months when all criteria are met.

    COPD continuation

    • Positive clinical response or disease stabilization, such as decreased exacerbations or improved pre-bronchodilator FEV1.
    • Member is at least 18 years old.
    • Member will continue maintenance COPD treatment, such as ICS with LAMA and LABA or LAMA and LABA, with mepolizumab.
    Oral corticosteroids unless contraindicated or not tolerated
    HES Threshold
    HES blood eosinophil countAt least 1000 cells per microliter
    Minimum age12 years or older
    Disease durationHES present for at least 6 months
    CRSwNP Objective Disease Threshold
    Polyp extentPolyps reach below the lower border of the middle turbinate or beyond in each nostril
    Disease patternBilateral nasal polyposis
    Assessment methodsNasal endoscopy, anterior rhinoscopy, or computed tomography may document the finding
    CRSwNP Objective Disease Threshold
    Meltzer Clinical Score2 or higher in both nostrils
    Condition assessedChronic rhinosinusitis with nasal polyps
    Alternative objective measureTotal endoscopic nasal polyp score of at least 5, with a minimum score of 2 for each nostril
    Endoscopic Nasal Polyp Score
    Total scoreAt least 5
    Per-nostril minimumAt least 2 for each nostril
    Alternative objective measuresMeltzer Clinical Score of 2 or higher in both nostrils, or polyps reaching below the lower border of the middle turbinate or beyond in each nostril
    COPD Spirometry Threshold
    Post-bronchodilation FEV1/FVCLess than 0.7
    PurposeSpirometric confirmation of COPD
    MeasurementForced expiratory volume in one second divided by forced vital capacity after bronchodilation
    COPD Eosinophil Threshold
    Absolute blood eosinophil countAt least 300 cells per microliter
    TimingBefore initiating therapy with the requested medication
    ConditionInadequately controlled COPD with an eosinophilic phenotype
    COPD Confirmation Threshold
    Spirometric confirmationPost-bronchodilation FEV1/FVC less than 0.7
    Minimum age18 years or older
    Clinical requirementClassic signs or symptoms of COPD
    COPD Eligibility Threshold
    Pretreatment absolute blood eosinophil countAt least 300 cells per microliter before initiating therapy
    Exacerbation alternativeAt least two moderate exacerbations treated with systemic glucocorticoids, antibiotics, or both, or at least one severe exacerbation requiring hospitalization or emergency care
    Maintenance therapyInhaled triple therapy with ICS, LAMA, and LABA, or LAMA and LABA when ICS is contraindicated
    Note

    Authorization Duration

    Authorization duration depends on the indication and request type.

    • Asthma: 6 months
    • CRSwNP: 6 months
    • EGPA: 12 months
    • HES: 12 months
    • COPD: 12 months
    Documentation Required

    Twelve-Month Authorization

    Twelve-month continuation authorization requires indication-specific criteria and documentation demonstrating the member meets the applicable age, disease-control, response, and concurrent-therapy requirements.

    • Asthma: improved control, age 6 years or older, and continued maintenance asthma therapy
    • EGPA: beneficial response, age 18 years or older
    • HES: reduced flares and age 12 years or older
    • CRSwNP: positive clinical response, age 18 years or older, and continued daily intranasal corticosteroid unless contraindicated or not tolerated
    • COPD: positive clinical response, age 18 years or older, and continued maintenance COPD therapy
    Step Therapy

    Asthma Optimized Controller Therapy

    For severe asthma, documentation must show inadequate control despite adherence to optimized doses of both a high-dose inhaled corticosteroid and an additional controller.

    • Additional controller may include a LABA, LAMA, leukotriene modifier, or sustained-release theophylline
    • The member must continue maintenance asthma treatments in combination with Nucala
    Documentation Required

    EGPA Corticosteroid Therapy

    For EGPA, the member must be currently taking an oral corticosteroid unless it is contraindicated or not tolerated.

    Step Therapy

    HES Concomitant Therapy

    For HES, Nucala must not be used as monotherapy. The member must be receiving a stable dose of HES therapy.

    • Examples include an oral corticosteroid, immunosuppressive therapy, or cytotoxic therapy
    Step Therapy

    CRSwNP Intranasal Corticosteroid Therapy

    For CRSwNP, chronic symptoms and bilateral nasal polyposis must persist despite at least 4 weeks of intranasal corticosteroid treatment, unless treatment is contraindicated or not tolerated. The member must continue a daily intranasal corticosteroid with Nucala unless contraindicated or not tolerated.

    Step Therapy

    COPD Maintenance Inhaler Therapy

    For COPD, the member must be receiving maintenance inhaler therapy with either triple therapy or LAMA/LABA when an ICS is contraindicated.

    • Triple therapy: ICS, LAMA, and LABA
    • Alternative when ICS is contraindicated: LAMA and LABA
    • Maintenance COPD therapy must continue with Nucala
    Step Therapy

    Prior COPD Biologic Therapy

    For COPD, document prior treatment with a biologic indicated for COPD when the request relies on prior biologic therapy.

    • The policy gives Dupixent as an example of a biologic indicated for COPD received within the past 12 months
    Prior Authorization

    Prior Authorization Submission

    Submit chart notes, medical records, or claims history supporting the applicable indication and whether the request is initial or continuation therapy.

    • Include all indication-specific clinical, laboratory, treatment, and response documentation required below
    Documentation Required

    Asthma Initial Documentation

    For an initial asthma request, submit documentation of previous medications tried and pretreatment disease status.

    • Previous medications: drug, dose, frequency, duration, and response when available
    • Pretreatment blood eosinophil count or dependence on systemic corticosteroids, if applicable
    Documentation Required

    Asthma Continuation Documentation

    For asthma continuation, submit chart notes or medical records supporting improvement in asthma control.

    • Examples include reduced symptom or exacerbation frequency/severity or reduced or discontinued daily maintenance oral corticosteroid dose
    Documentation Required

    EGPA Continuation Documentation

    For EGPA continuation, submit chart notes or medical records supporting a beneficial response to Nucala.

    • Examples include reduced relapse frequency, reduced or discontinued daily oral corticosteroid dose, or no active vasculitis
    Documentation Required

    HES Initial Documentation

    For an initial HES request, submit pretreatment laboratory results, fusion-gene testing, and prior treatment history.

    • Pretreatment blood eosinophil count
    • FIP1L1-PDGFRA fusion gene test results
    • Previous medications tried, including drug, dose, frequency, and duration
    Documentation Required

    HES Continuation Documentation

    For HES continuation, submit documentation of improved HES control and current FIP1L1-PDGFRA fusion-gene test results.

    • Document reduction in HES flares since starting Nucala
    Documentation Required

    CRSwNP Initial Documentation

    For an initial CRSwNP request, submit prior treatment and objective clinical documentation of nasal polyposis.

    • Previous medications tried, including drug, dose, frequency, and duration; include the clinical reason to avoid therapy if treatment is not advisable
    • Nasal endoscopy, anterior rhinoscopy, or CT findings, including polyp location and size when applicable
    • Meltzer Clinical Score or endoscopic nasal polyp score when applicable
    Documentation Required

    Initial CRSwNP Treatment and Polyp Documentation

    Initial CRSwNP documentation must establish prior treatment and objective polyp findings supporting coverage.

    • Bilateral nasal polyposis and chronic sinusitis symptoms despite at least 4 weeks of intranasal corticosteroid treatment, unless contraindicated or not tolerated
    • Prior sinonasal surgery or ineffective systemic corticosteroid treatment within the last 24 months, unless contraindicated or not tolerated
    • Objective findings may include polyps below the lower border of the middle turbinate, Meltzer Clinical Score of at least 2 in both nostrils, or total NPS of at least 5 with at least 2 per nostril
    Documentation Required

    CRSwNP Continuation Documentation

    For CRSwNP continuation, submit records supporting a positive clinical response to Nucala.

    • Document improvement in nasal congestion, polyp size, loss of smell, rhinorrhea, sinonasal inflammation, hyposmia, facial pressure or pain, or reduction in corticosteroid use
    Documentation Required

    Initial COPD Documentation

    For an initial COPD request, submit documentation of prior treatment, COPD symptoms, eosinophil count, and recent exacerbations.

    • Previous medications tried and response; if therapy was not advisable, document the clinical rationale to avoid it
    • Classic COPD signs or symptoms, where applicable
    • Absolute blood eosinophil count before initiating Nucala, where applicable
    • Moderate or severe exacerbation(s) within the past 12 months, where applicable
    Documentation Required

    Initial COPD Clinical Documentation

    For initial COPD coverage, clinical documentation must confirm the diagnosis and establish disease severity and treatment history.

    • Post-bronchodilator FEV1/FVC less than 0.7 on spirometry
    • Age 18 years or older and classic COPD symptoms
    • At least two moderate exacerbations treated with systemic glucocorticoids, antibiotics, or both, or at least one severe exacerbation requiring hospitalization or emergency care
    • Absolute blood eosinophil count of at least 300 cells per microliter before therapy
    • Current triple inhaled therapy or LAMA/LABA when ICS is contraindicated
    Documentation Required

    COPD Continuation Response

    For COPD continuation, submit records supporting a positive clinical response or stabilization of disease.

    • Document improved signs and symptoms, decreased exacerbations, improved pre-bronchodilator FEV1, or disease stabilization
    • Document age 18 years or older and continued maintenance COPD therapy

    Unsupported block type: denial_risk

    Denial Risk

    Acute Bronchospasm or Status Asthmaticus

    Acute bronchospasm and status asthmaticus are not covered because Nucala is not indicated for relief of acute symptoms.

    Denial Risk

    Unlisted Indications

    Indications not listed in the policy are considered experimental or investigational and are not medically necessary.

    Denial Risk

    HES Exclusions

    HES treatment is not covered when the member has an excluded underlying cause or genetic finding.

    • FIP1L1-PDGFRA kinase-positive HES
    • HES secondary to a non-hematologic cause, such as drug hypersensitivity, parasitic helminth infection, HIV infection, or non-hematologic malignancy
    Denial Risk

    Failure to Meet Indication Criteria

    Requests may be denied when applicable indication criteria are not met, including age, disease diagnosis or duration, laboratory values, exacerbation history, or required treatment criteria.

    • Criteria vary by asthma, EGPA, HES, CRSwNP, and COPD indication
    Denial Risk

    Concurrent Same-Indication Therapy

    The member cannot use Nucala concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Concomitant same-indication therapy may result in denial
    Denial Risk

    Insufficient COPD Exacerbation History

    COPD requests require at least two moderate exacerbations in the past 12 months treated with systemic corticosteroids, antibiotics, or both, unless the alternative severe-exacerbation criterion is met.

    Denial Risk

    COPD Eosinophil Threshold

    Before initiating Nucala for COPD, the member must have an absolute blood eosinophil count of at least 300 cells per microliter.

    Definitions
    AbbreviationEGPA
    Full termEosinophilic granulomatosis with polyangiitis
    Covered populationAdult patients
    Definitions
    MeasurePost-bronchodilation FEV1/FVC
    MeaningForced expiratory volume in one second divided by forced vital capacity measured after bronchodilation
    COPD criterionThe ratio must be less than 0.7
    Definitions
    EGPA relapseAn event requiring escalation of corticosteroid, immunosuppressive, or other therapy
    ExamplesAn increase in oral corticosteroid dose, initiation or increased dose of immunosuppressive therapy, or hospitalization
    Lookback periodAt least one relapse within 24 months before starting treatment, unless the disease is refractory
    Definitions
    Additional asthma controllerLABA, LAMA, leukotriene modifier, or sustained-release theophylline
    Required background therapyHigh-dose inhaled corticosteroid therapy at an optimized dose
    Treatment expectationMaintenance asthma treatments continue in combination with mepolizumab
    Definitions
    Post-bronchodilator FEV1/FVCForced expiratory volume in one second divided by forced vital capacity after bronchodilation
    COPD definition criterionThe ratio must be less than 0.7
    UseConfirms the COPD diagnosis for authorization
    Nucala CRSwNP Quantity Limit
    RouteSubcutaneous
    Minimum age18 years or older
    Maximum regimen100 mg every 4 weeks
    Nucala EGPA Quantity Limit
    RouteSubcutaneous
    Minimum age18 years or older
    Maximum regimen300 mg every 4 weeks as 3 separate 100-mg injections
    Nucala HES Quantity Limit
    RouteSubcutaneous
    Minimum age12 years or older
    Maximum regimen300 mg every 4 weeks as 3 separate 100-mg injections